Last reviewed · How we verify
di indolylmethane (DIM)
di indolylmethane (DIM) is a Indole Small molecule drug developed by New York Presbyterian Hospital. It is currently in Phase 3 development for Prostate cancer prevention.
DIM is a natural compound that acts as an estrogen receptor antagonist and a weak estrogen receptor agonist.
DIM is a natural compound that acts as an estrogen receptor antagonist and a weak estrogen receptor agonist. Used for Prostate cancer prevention.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | di indolylmethane (DIM) |
|---|---|
| Sponsor | New York Presbyterian Hospital |
| Drug class | Indole |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DIM has been shown to have anti-cancer properties by inhibiting the growth of cancer cells and inducing apoptosis. It also has anti-inflammatory and antioxidant effects.
Approved indications
- Prostate cancer prevention
Common side effects
- Nausea
- Diarrhea
Key clinical trials
- Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia (PHASE3)
- Diindolylmethane in Preventing Cancer in Healthy Volunteers (PHASE1)
- The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- di indolylmethane (DIM) CI brief — competitive landscape report
- di indolylmethane (DIM) updates RSS · CI watch RSS
- New York Presbyterian Hospital portfolio CI
Frequently asked questions about di indolylmethane (DIM)
What is di indolylmethane (DIM)?
How does di indolylmethane (DIM) work?
What is di indolylmethane (DIM) used for?
Who makes di indolylmethane (DIM)?
What drug class is di indolylmethane (DIM) in?
What development phase is di indolylmethane (DIM) in?
What are the side effects of di indolylmethane (DIM)?
What does di indolylmethane (DIM) target?
Related
- Drug class: All Indole drugs
- Target: All drugs targeting Estrogen receptor
- Manufacturer: New York Presbyterian Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing